Uploaded by PHGFoundation on Oct 8, 2008
View the full Interactive Tutorial at:
http://www.phgfoundation.org/tutorials/pharmacogenomics/5.html
Some of the most advanced applications of pharmacogenetic knowledge are those in the field of cancer therapeutics. Cancer is an unusual disease, as it arises through the accumulation of multiple mutations in certain genes within a cell, that together act to disrupt the normal checks and controls over cellular function and replication. This leads to uncontrolled and inappropriate cellular proliferation. Cancer cells therefore have distinct genetic profiles; increasing understanding of the molecular genetics of cancer is making it possible to exploit the differences between normal and cancerous cells to target therapeutics.
The major problem with conventional chemotherapy is that to achieve reasonable efficacy, a substantial degree of toxicity (and hence significant adverse side-effects) is required. Targeting drugs or other therapeutics more specifically to tumour cells both increases efficacy and reduces toxicity.
Herceptin
One of the best known examples of genetic targeting is that of HerceptinĀ® (generic name trastuzumab). This is an antibody-based (biological) therapeutic used for the treatment of HER2 positive breast cancers, ie. those that produce abnormally high levels of human epidermal growth factor, ~20% of all breast cancers. Breast cancer cells that produce high levels of HER2, a cell surface molecule, are stimulated to replicate by the binding of HER2. Herceptin competitively binds to HER2, blocking growth factor binding and targeting the cancer cells for destruction by the bodys own systems. Non-cancerous cells do not produce large amounts of HER2 and are relatively unaffected, reducing the toxicity of the treatment. Purists might argue that the design of therapeutics such as Herceptin and GlivecĀ® (generic name imatinib) do not represent true pharmacogenetics, because they are specifically targeted to the genetic nature of the tumour cells, as opposed to the patients genotype, but the commercial success of these agents has had a significant impact on the profile of pharmacogenetics as a tool for drug design and development.
Category:
Tags:
License:
Standard YouTube License
-
8 likes, 0 dislikes
-
1:14
Pharmacogenomics - Clinical Implicationsby PHGFoundation3,027 views
1:25
Pharmacogenomics - The Futureby PHGFoundation3,655 views
1:08
Pharmacogenomics - Introductionby PHGFoundation8,403 views
1:42
Pharmacogenomics - Variation in Drug Responsesby PHGFoundation9,603 views
2:52
The Drug Discovery Processby PhRMAPress8,881 views
3:55
Herceptin: A Multimodal Approach Targeting HER2 Positive Breast Cancerby tecknowledge200019,938 views
5:07
CNN Cancer and Genetics Part II - Previvors and Genetic Testingby Previvors944 views
5:31
From Molecule to Medicineby NorvellJefferson12,730 views
1:06
Disco Docking - Computational Drug Designby CompChemist12,099 views
0:25
Herceptin (Trastuzumab)by RedAndr5,138 views
1:01
A Herceptin treatmentby littleone9285,744 views
1:07
3D Medical Animation - What is Cancer?by biodigitalsystems875,530 views
0:33
Herceptin: Mechanism of actionby CancerQuest25,891 views
1:18
DNA Test Methods - DNA Microarraysby PHGFoundation43,236 views
7:14
Oncogenetic Labs - Revolutionary New Cancer Testingby OncogeneticLabs1,610 views
1:01
Gold Nanoparticles and Cancer Cell Detectionby katyImpala94,443 views
1:15
Pharmacology: Drug bindingby bmedinago54,401 views
0:20
SNPs - Single Nucleotide Polymorphismsby blaineb560,548 views
2:26
Gleevecs mechanism of Actionby URIanimation47,448 views
9:59
Professor gave us a seminar about drug design 1by jeholee3,288 views
- Loading more suggestions...
Link to this comment:
All Comments (1)